Abstract
Chiral high performance liquid chromatography method for the separation of (R)-5-(1- Hydroxyethyl)-2-(pyridine-2-yl)-[1, 3, 4]-thiadiazole (R-alcohol) an intermediate of new antibiotic Nafithromycin (NFT) has been developed and validated. NFT is a ketolide class of antibiotic currently under Phase III clinical trials in India to treat community acquired bacterial pneumonia. Chiral separation of the enantiomers with resolution >2 was accomplished on Chiralpak IA column using a mixture of n-hexane and isopropanol (IPA) in the ratio of (90:10; v/v) as an elution solvent, run at a flow rate of 1.2 mL.min-1. The column was maintained at 25°C. The analytes were detected at 254 nm. The developed method was extensively validated as per the international council for harmonisation of technical requirements for pharmaceuticals for human use guideline. Sensitivity of the method was adequate to control the passage of unwanted enantiomer to next step with limit of quantification (LOQ) of the undesired enantiomer (S)-5-(1-Hydroxyethyl)-2-(pyridine- 2-yl)-[1, 3, 4]-thiadiazole (S-alcohol) of 0.37 µgmL-1. Mean recovery of the S-alcohol was 98.9±8.7%. During development influence of column oven temperature on the chiral separation was assessed.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
